“Hong Kong Medical Block Chain MCHK” glory set sail
“Hong Kong Medical Block Chain MCHK” participated in the “20th China International Investment and Trade Fair”
1.On September 9, 2018, at the twentieth session of the China International Fair for Investment and Trade, more than 1,000 industrial and commercial groups, about 5,000 companies and more than 120,000 merchants from more than 110 countries and regions gathered in Xiamen .Medisun Medical Group participated in the forum.
The Medisun market team gathered at the Hong Kong medical block chain MCHK at the center booth of Xiajiahui
Terry Lierman (left), Chairman of Medisun Medical Group, and Mr. Danny Wong (right), Executive Chairman, at the “Hong Kong Medical Block Chain” booth
“Hong Kong Medical Block Chain MCHK” hosted the “Blockchain 3.0 Energizing Entity Economic Forum”
Organized by the China Investment Association, Tsinghua x-lab Ivy League Research Institute and Medisun Medical Group’s “Block Chain 3.0 Energizing Entity Economic Forum” became a highlight of the current Xiamen Fair.
Blockchain 3.0 empowers the real economy and has become a new consensus in China’s blockchain industry. Blockchain 3.0 represents the Internet of Things-based blockchain 3.0 technology that truly links the digital economy to the real economy to form a complete blockchain technology, business and financial services ecosystem for the service industry.
Terry Lierman, Chairman of Medisun Medical Group, addressed the investment forum
Mr. Danny Wong (first from right), Chairman of the Medisun Medical Group, signed the strategic cooperation of the “Ticket Reform Laboratory”
Terry Lierman, Chairman of Medisun Medical Group, introduced the Hong Kong medical block chain MCHK
Terry Lierman, Chairman of the American Medical Group, said that the most critical factors in the health care system are Transparecny, Quality and Access. The reason why the US medical system does not have such an accident in China is because the US FDA adheres to the standard approval and monitoring process for medical products. This is the effectiveness of the medical system. The Hong Kong medical blockchain will also be reliable. The medical platform is based on blockchain technology. Any vaccine products and medical products are produced, circulated and used on the MCHK platform are transparent and traceable.
“Hong Kong Medical Chain Chain MCHK”, as the Hong Kong medical service public chain, is based on the collection of 500 advanced medical institutions in Hong Kong. It integrates 5,000 medical institutions in the Greater Bay Area within three years, and uses the blockchain technology as a framework to integrate Medisun Medical The Group’s rich clinical research and development technology and experience in regenerative Medisun have enhanced the trust and consensus of the children’s vaccine and cancer vaccine industry, promoted the integration and upgrading of the medical industry in Dawan District, and achieved the first to meet the international standard level in the “9+2 City” medical service system in Dawan District.
“Hong Kong Medical Block Chain MCHK” won the “Blockchain Innovation Enterprise Award”
This forum held the awarding ceremony of “Blockchain 3.0 Encouraging Entity Economy Top Ten Innovative Enterprises”. “Hong Kong Medical Block Chain MCHK” won the award as the latest medical health platform based on blockchain technology.
Mr. Danny Wong (third from left), Executive Chairman of Medisun Medical Group, received the award.
Launching Ceremony of “Hong Kong Medical Blockchain MCHK”
On September 10th, the launching ceremony of the Hong Kong medical block chain MCHK was held in Xiamen. The chairman of the group, Terry Lierman, and the executive chairman of the group, Mr. Danny Wong, co-chaired and opened the champagne. The marketing team raised a toast to celebrate this memorable day!
Hong Kong Medical Block Chain MCHK Launch Ceremony
MCHK “Hong Kong Medical Block Chain” Hong Kong Medical Services Public Link is a joint venture of Medisun Medical Group.
Headquartered in Hong Kong, Medisun Medical Group is a professional medical investment group dedicated to the research and development and commercialization of global regenerative product technology, as well as quality hospitals and treatment centers. Medisun has long-term cooperation with the Johns Hopkins Life Science Center and the Harvard University Stem Cell Institute, working on the investment and research and development of new technologies in the field of regenerative worldwide, and conducting clinical trials in many well-known hospitals in mainland China and Hong Kong; In cooperation with Tsinghua University, Medisun established the “Medical Institute of Cell Technology of Tsinghua University” and “Medical University Tsinghua University Regenerative Medisun Industry Fund”.
The Medisun Regenerative Centre is located in Kowloon Bay, Hong Kong. It has an international GMP standard medical laboratory, cancer treatment center and anti-aging center. It provides immune cell therapy, a variety of stem cell health treatments, a number of child and adult vaccinations and a full range of biomedical products. Testing to provide customers with the most predictable health protection.
For more information, please visit http://www.medisun.hk/